
Blends
CJC-1295 + Ipamorelin
A single vial containing CJC-1295 (no DAC) and ipamorelin. One is a GHRH-receptor agonist and the other a ghrelin-receptor agonist; published research examines them individually, not as this combination.
- Container
- Glass vial, crimp seal, flip-top cap
- Storage
- -20 °C, desiccated
- In the vial
- CJC-1295 (no DAC) + Ipamorelin
- Paperwork
- Lot certificate (HPLC + mass spec) shown before you pay
Lot certificates
You’ll see American Peptides on the lab’s copy. They’re our supplier.
- 5 mg / 5 mg, lot CJCIP10-0803: 99.80% purity (RP-HPLC), 5.13 mg / 5.55 mg measured, identity confirmed by mass spec. Issued 2026-08-28 by Bioviridian Inc.. Verify certificate COA7607
- 10 mg / 10 mg, lot CJCIP20-0803: 99.82% purity (RP-HPLC), 10.62 mg / 10.55 mg measured, identity confirmed by mass spec. Issued 2026-08-28 by Bioviridian Inc.. Verify certificate COA7631
Our vials are filled from lots made by our supplier, American Peptides, and tested by Bioviridian Inc.The laboratory’s original certificate lists American Peptides as the vendor. Look up the code at bioviridians.com to check it.
What researchers study it for
- Structural analog of GHRH(1-29)
- Doping-control detection in seized material
- Selective growth hormone release
- Pituitary hormone selectivity in animal models
How it is thought to work
CJC-1295 (no DAC): As a GHRH(1-29) analog, it is expected to act on the GHRH receptor of pituitary somatotrophs, but this is inferred from related compounds rather than measured directly. Ipamorelin: Ipamorelin acts on the ghrelin receptor (GHS-R1a), stimulating growth hormone release from the pituitary.
Where the research stands
Blend of research compounds. Each component is studied separately; as a combined vial it has no dedicated published research. The least-established component is CJC-1295 (no DAC): no published human studies.
Sources
- Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.. Endocrinology.
- Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M (2026). The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.. Front Endocrinol (Lausanne).
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH (1998). Ipamorelin, the first selective growth hormone secretagogue.. Eur J Endocrinol.
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.. Pharm Res.
Read more
For laboratory research use only. Not a drug, food, supplement or cosmetic; not for human or veterinary use. Nothing on this page is medical advice or a usage guide.
